Medical Advocates for Social Justice

   Medical Advocates for Social Justice

Kaletra Library Service 
 Conference Abstracts and Posters
   
  Index of  Abstracts and Posters from 
11th Conference on Retroviruses and Opportunistic Infections
 San Francisco, CA, USA
 February 08-11, 2004


 

CONFERENCE PDF POSTER
Once-Daily vs. Twice-Daily Lopinavir/ritonavir in Antiretroviral-Naïve Patients: 48-Week Results
 J Gathe, D Podzamczer, M Johnson, et al.
 PDF Poster

CONFERENCE PDF POSTER
Lopinavir Inhibitory Quotient Predicts Virologic Response in Highly Antiretroviral-experienced
Patients Receiving High-dose Lopinavir/Ritonavir
 R Bertz, J Li, M King,  et al
 PDF Poster      Abstract   
 
CONFERENCE PDF POSTER
 Evaluation of HCV RNA and Liver Injury in HCV/HIV Coinfected Patients Initiating Lopinavir/or
Nelfinavir-based Therapy
 KE Sherman, NJ Shire, P Cernohous, et al.
 PDF Poster
 
CONFERENCE PDF POSTER
Predictive Factors of Virological Success in PI-naive and -experienced HIV-infected Children
Treated with a Regimen Including Lopinavir/Ritonavir
 C Delaugerre, JP Teglas, JM Treluyer, et al.  
PDF Poster        Abstract  
 
CONFERENCE PDF POSTER
 Pharmacologic Management of the Drug-Drug Interaction between Lopinavir/Ritonavir
and Amprenavir
HE Wynn Vezina, RC Brundage, L Bushman, CV Fletcher
PDF Poster         Abstract|
 
CONFERENCE POWERPOINT POSTER
 Efficacy and Safety of Atazanavir (ATV) With Ritonavir (RTV) or Saquinavir (SQV) vs
Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Experienced Virologic Failure on
Multiple HAART Regimens: 48-Week Results From BMS AI424-045
 E DeJesus, B Grinsztejn, C Rodriguez, et al
Poster

Predictive Power of Genotypic Inhibitory Quotient and Lopinavir Plasma Levels in both
Efficacy and Lipid Elevations of LPV/r -based Salvage Regimens at 48 Weeks
D González de Requena, T García-Benayas, O Gallego, et al 
Abstract

Synergistic Activity of Lopinavir and Saquinavir on Protease Inhibitor-resistant HIV-1
E Dam, S Rochas, J L Faudon, et al.
Abstract
 
Pharmacokinetics and Safety of Lopinavir/ritonavir Doses Greater than 300 mg/m2/ in |
Children and Adolescents with HIV Infection
P Havens M Frank, B Cuene, et al
Abstract
 
KLS Main Page   KLS Conference  Index  Home

11th Conference on Retroviruses and Opportunistic Infections
 Index of Kaletra Data
© 2004 Medical Advocates for Social Justice